Publications by authors named "Natasha Leighl"

100Publications

Can Oncologists Predict the Efficacy of Treatments in Randomized Trials?

Oncologist 2020 Jul 27. Epub 2020 Jul 27.

Biomedical Ethics Unit, McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2020-0054DOI Listing
July 2020

The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data.

Qual Life Res 2020 Aug 26. Epub 2020 Aug 26.

Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON, M5G2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-020-02615-1DOI Listing
August 2020

Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.

Lung Cancer 2020 Sep 26;147:214-220. Epub 2020 Jul 26.

University Health Network, University of Toronto, 610 University Avenue Toronto, M5G2M9, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.07.020DOI Listing
September 2020

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy.

Cancers (Basel) 2020 Jul 16;12(7). Epub 2020 Jul 16.

Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12071926DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409233PMC
July 2020

Mechanisms of osimertinib resistance and emerging treatment options.

Lung Cancer 2020 Sep 18;147:123-129. Epub 2020 Jul 18.

University Health Network, Princess Margret Cancer Centre, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.07.014DOI Listing
September 2020

BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.

Lung Cancer 2020 08 21;146:78-85. Epub 2020 May 21.

University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Dalla Lana School of Public Health and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.05.018DOI Listing
August 2020

EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models.

Lung Cancer 2020 07 11;145:144-151. Epub 2020 May 11.

University Health Network, Ontario Cancer Institute/Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Departments of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health and Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2020.03.022DOI Listing
July 2020

TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.

Cancer Cell 2020 06 16;37(6):742-745. Epub 2020 May 16.

Department of Medicine, Division of Hematology & Oncology, Vanderbilt University Medical Center, Nashville, TN, USA; Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2020.05.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7229923PMC
June 2020

Protein-altering germline mutations implicate novel genes related to lung cancer development.

Authors:
Xuemei Ji Semanti Mukherjee Maria Teresa Landi Yohan Bosse Philippe Joubert Dakai Zhu Ivan Gorlov Xiangjun Xiao Younghun Han Olga Gorlova Rayjean J Hung Yonathan Brhane Robert Carreras-Torres David C Christiani Neil Caporaso Mattias Johansson Geoffrey Liu Stig E Bojesen Loic Le Marchand Demetrios Albanes Heike Bickeböller Melinda C Aldrich William S Bush Adonina Tardon Gad Rennert Chu Chen Jinyoung Byun Konstantin H Dragnev John K Field Lambertus Fa Kiemeney Philip Lazarus Shan Zienolddiny Stephen Lam Matthew B Schabath Angeline S Andrew Pier A Bertazzi Angela C Pesatori Nancy Diao Li Su Lei Song Ruyang Zhang Natasha Leighl Jakob S Johansen Anders Mellemgaard Walid Saliba Christopher Haiman Lynne Wilkens Ana Fernandez-Somoano Guillermo Fernandez-Tardon Erik H F M van der Heijden Jin Hee Kim Michael P A Davies Michael W Marcus Hans Brunnström Jonas Manjer Olle Melander David C Muller Kim Overvad Antonia Trichopoulou Rosario Tumino Gary E Goodman Angela Cox Fiona Taylor Penella Woll Erich Wichmann Thomas Muley Angela Risch Albert Rosenberger Kjell Grankvist Mikael Johansson Frances Shepherd Ming-Sound Tsao Susanne M Arnold Eric B Haura Ciprian Bolca Ivana Holcatova Vladimir Janout Milica Kontic Jolanta Lissowska Anush Mukeria Simona Ognjanovic Tadeusz M Orlowski Ghislaine Scelo Beata Swiatkowska David Zaridze Per Bakke Vidar Skaug Lesley M Butler Kenneth Offit Preethi Srinivasan Chaitanya Bandlamudi Matthew D Hellmann David B Solit Mark E Robson Charles M Rudin Zsofia K Stadler Barry S Taylor Michael F Berger Richard Houlston John McLaughlin Victoria Stevens David C Nickle Ma'en Obeidat Wim Timens María Soler Artigas Sanjay Shete Hermann Brenner Stephen Chanock Paul Brennan James D McKay Christopher I Amos

Nat Commun 2020 05 11;11(1):2220. Epub 2020 May 11.

The Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-020-15905-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214407PMC
May 2020

Early Detection of Multiple Resistance Mechanisms by ctDNA Profiling in a Patient With EGFR-mutant Lung Adenocarcinoma Treated With Osimertinib.

Clin Lung Cancer 2020 Sep 9;21(5):e488-e492. Epub 2020 Apr 9.

University Health Network, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2020.03.009DOI Listing
September 2020

Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach?

Cancer 2020 Jul 4;126(14):3176-3180. Epub 2020 May 4.

Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32875DOI Listing
July 2020

Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study.

CMAJ Open 2020 Jan-Mar;8(1):E191-E198. Epub 2020 Mar 16.

Sunnybrook Research Institute (Mittmann, Seung) and Odette Cancer Centre (Look Hong, Earle, Cheung, Coburn, DeAngelis), Sunnybrook Health Sciences Centre; Cancer Care Ontario (Mittmann), Toronto, Ont.; Canadian Agency for Drugs and Technologies in Health (Mittmann), Ottawa, Ont.; ICES (Liu, Cheng, Saxena, Earle, Cheung, Coburn); Health Outcomes and PharmacoEconomic (HOPE) Research Centre (Seung); University Health Network (Leighl), Toronto, Ont.; McMaster University (Evans), Hamilton, Ont.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.9778/cmajo.20190114DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082106PMC
March 2020

Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases.

J Pain Symptom Manage 2020 Aug 5;60(2):422-429.e1. Epub 2020 Mar 5.

Department of Supportive Care, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpainsymman.2020.02.023DOI Listing
August 2020

Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.

Cancer Treat Rev 2020 Apr 4;85:101979. Epub 2020 Feb 4.

Yale University & Yale Comprehensive Cancer Center, New Haven, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.101979DOI Listing
April 2020

Advancing the systemic therapy of lung cancer: quality or quantity?

Lancet Oncol 2020 03 6;21(3):322-324. Epub 2020 Feb 6.

Division of Medical Oncology/Hematology, Princess Margaret Cancer Centre, University of Toronto, ON M5G 1Z5, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(20)30076-0DOI Listing
March 2020

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.

Eur J Cancer 2020 01 12;125:49-57. Epub 2019 Dec 12.

Department of Oncology, University of Turin, Azienda Ospedaliero-Universitaria San Luigi Gonzaga, Turin, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.11.006DOI Listing
January 2020

Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma.

J Thorac Cardiovasc Surg 2020 05 30;159(5):2043-2054.e9. Epub 2019 Sep 30.

Division of Thoracic Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtcvs.2019.09.077DOI Listing
May 2020

Improving the Management of Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.

J Oncol Pract 2019 11;15(11):571-572

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00575DOI Listing
November 2019

Hyperprogressive disease with immunotherapy: new directions.

J Thorac Dis 2019 Sep;11(Suppl 15):S1877-S1880

Princess Margaret Cancer Center, University Health Network, Toronto ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2019.08.88DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783768PMC
September 2019

Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.

Lung Cancer 2019 08 29;134:259-267. Epub 2019 May 29.

Cross Cancer Institute and University of Alberta, 11560 University Ave, Edmonton, AB, T6G 1Z2, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002193047
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2019.05.027DOI Listing
August 2019

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial.

BMC Cancer 2019 Jun 7;19(1):552. Epub 2019 Jun 7.

Division of Health Policy and Management, Department of Public Health Sciences and Associate Director, Center for Healthcare Policy and Research, 2103 Stockton Blvd, Sacramento, CA, 95817, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5779-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555934PMC
June 2019

Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario.

J Oncol Pharm Pract 2020 Mar 2;26(2):379-385. Epub 2019 Jun 2.

Canadian Centre for Applied Research in Cancer Control (ARCC), Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219850299DOI Listing
March 2020

Emerging therapies for non-small cell lung cancer.

J Hematol Oncol 2019 04 25;12(1):45. Epub 2019 Apr 25.

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, People's Republic of China.

View Article

Download full-text PDF

Source
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-
Publisher Site
http://dx.doi.org/10.1186/s13045-019-0731-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482588PMC
April 2019

Improving lung cancer diagnosis: the evolving role of patients and care providers.

J Thorac Dis 2019 Mar;11(Suppl 3):S422-S424

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.11.68DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424746PMC
March 2019

Genetic interaction analysis among oncogenesis-related genes revealed novel genes and networks in lung cancer development.

Oncotarget 2019 Mar 5;10(19):1760-1774. Epub 2019 Mar 5.

Biomedical Data Science Department, Dartmouth College, Hanover, NH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26678DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442994PMC
March 2019

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.

Clin Lung Cancer 2019 07 22;20(4):231-236. Epub 2018 Dec 22.

Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.010DOI Listing
July 2019

The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.

Curr Treat Options Oncol 2019 02 18;20(3):21. Epub 2019 Feb 18.

Princess Margaret Cancer Centre, Division of Medical Oncology, University of Toronto, 7-913 700 University Avenue, Toronto, ON, M5G 1Z5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-019-0617-6DOI Listing
February 2019

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer.

Clin Lung Cancer 2019 05 19;20(3):e338-e345. Epub 2018 Dec 19.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and Department of Medicine, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.009DOI Listing
May 2019

The role of cytology in molecular testing and personalized medicine in lung cancer: A clinical perspective.

Cancer Cytopathol 2019 02 4;127(2):72-78. Epub 2018 Dec 4.

Division of Medical Oncology, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncy.22085
Publisher Site
http://dx.doi.org/10.1002/cncy.22085DOI Listing
February 2019

Systemic Therapy Use and Outcomes After Relapse from Preoperative Radiation and Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma.

Oncologist 2019 07 26;24(7):e510-e517. Epub 2018 Nov 26.

Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656469PMC
July 2019

Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.

Lung Cancer 2018 11 30;125:1-7. Epub 2018 Aug 30.

Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.08.024DOI Listing
November 2018

The Value of Biomarkers in Optimizing the Use of Immuno-oncologic Therapy.

Curr Drug Targets 2019 ;20(1):81-86

Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450119666180911093143DOI Listing
February 2020

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 Aug 28:JCO2018783118. Epub 2018 Aug 28.

Thanyanan Reungwetwattana, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Kazuhiko Nakagawa, Kindai University School of Medicine, Osaka; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; Isamu Okamoto, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Byoung Chul Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul; Eun Kyung Cho, Gachon University Gil Medical Center, Incheon; Ki Hyeong Lee, Chungbuk National University Hospital, Cheong-ju, Republic of Korea; Manuel Cobo, Institute of Biomedical Research in Málaga, Málaga University Hospital Regional, Málaga, Spain; Alessandro Bertolini, Hospital of Sondrio, Sondrio, Italy; Sabine Bohnet, Universitätsklinik Schleswig-Holstein, Lübeck, Germany; Caicun Zhou, Pulmonary Hospital of Tongji University, Shanghai, People's Republic of China; Natasha Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Rachel Hodge, Astrid McKeown, Andrew P. Brown, and Yuri Rukazenkov, AstraZeneca, Cambridge, United Kingdom; Suresh S. Ramalingam, Winship Cancer Institute, Emory University, Atlanta, GA; and Johan Vansteenkiste, University Hospital, Katholieke Universiteit Leuven, Leuven, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.3118DOI Listing
August 2018

Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk.

Authors:
Xuemei Ji Yohan Bossé Maria Teresa Landi Jiang Gui Xiangjun Xiao David Qian Philippe Joubert Maxime Lamontagne Yafang Li Ivan Gorlov Mariella de Biasi Younghun Han Olga Gorlova Rayjean J Hung Xifeng Wu James McKay Xuchen Zong Robert Carreras-Torres David C Christiani Neil Caporaso Mattias Johansson Geoffrey Liu Stig E Bojesen Loic Le Marchand Demetrios Albanes Heike Bickeböller Melinda C Aldrich William S Bush Adonina Tardon Gad Rennert Chu Chen M Dawn Teare John K Field Lambertus A Kiemeney Philip Lazarus Aage Haugen Stephen Lam Matthew B Schabath Angeline S Andrew Hongbing Shen Yun-Chul Hong Jian-Min Yuan Pier A Bertazzi Angela C Pesatori Yuanqing Ye Nancy Diao Li Su Ruyang Zhang Yonathan Brhane Natasha Leighl Jakob S Johansen Anders Mellemgaard Walid Saliba Christopher Haiman Lynne Wilkens Ana Fernandez-Somoano Guillermo Fernandez-Tardon Erik H F M van der Heijden Jin Hee Kim Juncheng Dai Zhibin Hu Michael P A Davies Michael W Marcus Hans Brunnström Jonas Manjer Olle Melander David C Muller Kim Overvad Antonia Trichopoulou Rosario Tumino Jennifer Doherty Gary E Goodman Angela Cox Fiona Taylor Penella Woll Irene Brüske Judith Manz Thomas Muley Angela Risch Albert Rosenberger Kjell Grankvist Mikael Johansson Frances Shepherd Ming-Sound Tsao Susanne M Arnold Eric B Haura Ciprian Bolca Ivana Holcatova Vladimir Janout Milica Kontic Jolanta Lissowska Anush Mukeria Simona Ognjanovic Tadeusz M Orlowski Ghislaine Scelo Beata Swiatkowska David Zaridze Per Bakke Vidar Skaug Shanbeh Zienolddiny Eric J Duell Lesley M Butler Woon-Puay Koh Yu-Tang Gao Richard Houlston John McLaughlin Victoria Stevens David C Nickle Ma'en Obeidat Wim Timens Bin Zhu Lei Song María Soler Artigas Martin D Tobin Louise V Wain Fangyi Gu Jinyoung Byun Ahsan Kamal Dakai Zhu Rachel F Tyndale Wei-Qi Wei Stephen Chanock Paul Brennan Christopher I Amos

Nat Commun 2018 08 13;9(1):3221. Epub 2018 Aug 13.

Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, 03750, NH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-05074-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089967PMC
August 2018

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.

Lung Cancer 2018 09 19;123:22-29. Epub 2018 Jun 19.

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183043
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.06.023DOI Listing
September 2018

Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461).

Clin Lung Cancer 2018 09 16;19(5):e699-e703. Epub 2018 May 16.

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.05.002DOI Listing
September 2018

Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors.

CNS Drugs 2018 06;32(6):527-542

Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, 7W-389, 700 University Avenue, Toronto, ON, M5G 1Z5, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40263-018-0526-4
Publisher Site
http://dx.doi.org/10.1007/s40263-018-0526-4DOI Listing
June 2018

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

J Clin Oncol 2018 06 14;36(17):1714-1768. Epub 2018 Feb 14.

Julie R. Brahmer, Johns Hopkins Kimmel Cancer Center; Jennifer S. Mammen, Johns Hopkins University, Baltimore, MD; Christina Lacchetti, American Society of Clinical Oncology, Alexandria; Alexander Spira, Virginia Cancer Specialists and US Oncology Research, Fairfax, VA; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Michael B. Atkins, Georgetown Lombardi Comprehensive Cancer Center; Cristina A. Reichner, Georgetown University; Laura D. Porter, Colon Cancer Alliance; Washington, DC; Kelly J. Brassil, Aung Naing, Loretta J. Nastoupil, Maria E. Suarez-Almazor, and Yinghong Wang, MD Anderson Cancer Center, Houston, TX; Jeffrey M. Caterino, The Ohio State University Wexner Medical Center, Columbus, OH; Ian Chau, The Royal Marsden Hospital and Institute of Cancer Research, London and Surrey, United Kingdom; Marc S. Ernstoff and Igor Puzanov, Roswell Park Cancer Institute, Buffalo; Bianca D. Santomasso and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center; Jeffrey S. Weber, New York University Langone Medical Center, New York, NY; Pamela Ginex, Oncology Nursing Society, Pittsburgh, PA; Jennifer M. Gardner, Seattle Cancer Care Alliance and University of Washington, Seattle, WA; Sigrun Hallmeyer, Oncology Specialists SC, Park Ridge, IL; Jennifer Holter Chakrabarty, University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; David F. McDermott, Beth Israel Deaconess Medical Center; Carole Seigel, Massachusetts General Hospital Cancer Center, Boston, MA; John A. Thompson, Seattle Cancer Care Alliance, University of Washington, and the Fred Hutchinson Cancer Research Center, Seattle, WA; and Tanyanika Phillips, CHRISTUS St Frances Cabrini Cancer Center, Alexandria, LA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.6385DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481621PMC
June 2018

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update.

J Clin Oncol 2018 03 5;36(9):911-919. Epub 2018 Feb 5.

Gregory P. Kalemkerian and Madelyn Lew, University of Michigan, Ann Arbor; James Pantelas, Greater Detroit Area; Michael Simoff, Henry Ford Hospital, Detroit, MI; Navneet Narula, Weill Cornell Medical College; Jessica Donington, New York University School of Medicine: Anjali Saqi, Columbia University Medical Center, New York, NY; Erin B. Kennedy, American Society of Clinical Oncology, Alexandria, VA; William A. Biermann, Chestnut Hill Hospital and Mercy Suburban Hospital, East Norriton; Baskaran Sundaram, Thomas Jefferson Medical School, Philadelphia, PA; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, ON, Canada; Suresh S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, GA; Martin Reck, Lung Clinic Grosshansdorf, Grosshansdorf, Germany; and Navneet Singh, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.7293
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.7293DOI Listing
March 2018

Personalized medicine for non-small cell lung cancer: where are we now and where can we go?

Expert Rev Respir Med 2018 02 5;12(2):81-82. Epub 2017 Dec 5.

a Division of Medical Oncology and Hematology , Princess Margaret Cancer Centre/University Health Network , Toronto , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17476348.2018.1411805DOI Listing
February 2018

Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population.

Carcinogenesis 2018 03;39(3):336-346

Biomedical Data Science Department, Dartmouth College, Hanover, NH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgx113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6248554PMC
March 2018

Case for Stopping Targeted Therapy When Lung Cancer Progresses on Treatment in Hospice-Eligible Patients.

J Oncol Pract 2017 12 5;13(12):780-783. Epub 2017 Oct 5.

Johns Hopkins, Baltimore, MD; Indiana University, Bloomington, IN; UT Southwestern Medical School, Dallas, TX; Virginia Commonwealth University Massey Cancer Center, Richmond; Inova Schar Cancer Institute, Falls Church; ASCO, Alexandria, VA; Einstein Medical Center, Philadelphia, PA; Juravinski Cancer Centre, Hamilton; Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Lombardi Cancer Center, Washington, DC; Lahey Hospital & Medical Center, Burlington, MA; William Beaumont Hospital, Royal Oak; University of Michigan, Ann Arbor, MI; Memorial Sloan Kettering Cancer Center, New York, NY; Circle of Hope for Cancer Research, St Cloud, FL; and Helen F. Graham Cancer Center, Newark, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.027367DOI Listing
December 2017

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

J Clin Oncol 2017 Nov 11;35(31):3591-3600. Epub 2017 Sep 11.

Federica Grosso, Azienda Ospedaliera SS Antonio e Biagio General Hospital, Alessandria; Silvia Novello and Giorgio Scagliotti, L'università di Torino, Azienda Sanitaria Ospedale San Luigi Gonzaga, Turin, Italy; Anna K. Nowak, University of Western Australia, Crawley, and Sir Charles Gairdner Hospital, Nedlands, Western Australia; Thomas John, Olivia Newton-John Cancer Research Institute, Austin Hospital, Heidelberg, Victoria, Australia; Sanjay Popat, The Royal Marsden Hospital National Health Service (NHS) Foundation Trust, London; Nicola Steele, The Beatson West of Scotland Cancer Centre, Glasgow; Paul Taylor, University Hospitals of South Manchester NHS Trust, Wythenshawe, Manchester, United Kingdom; Laurent Greillier, Assitance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille; David Planchard, Institut Gustave Roussy, Villejuif; Nassim Morsli, Boehringer Ingelheim France S.A.S., Paris, France; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Martin Reck, Lung Clinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf; Ute von Wangenheim, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; Jens Benn Sørensen, Rigshospitalet - Finsencentret, Copenhagen, Denmark; Mark A. Socinski, Florida Hospital Cancer Institute, Orlando, FL; Arsène Bienvenu Loembé, Boehringer Ingelheim B.V., Alkmaar, the Netherlands; and José Barrueco, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.9012DOI Listing
November 2017

Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.

Pharmacoeconomics 2017 Dec;35(12):1195-1209

Princess Margaret Cancer Center, University Health Network, c/o 700 University Avenue, Room 7-913, Toronto, ON, M5G 1Z5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40273-017-0563-8DOI Listing
December 2017

Chemotherapy and radiation treatment decision-making experiences of older adults with cancer: A qualitative study.

J Geriatr Oncol 2018 01 19;9(1):47-52. Epub 2017 Aug 19.

Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2017.07.013DOI Listing
January 2018

Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

J Clin Oncol 2017 Oct 14;35(30):3484-3515. Epub 2017 Aug 14.

Nasser Hanna, Indiana University Simon Cancer Center, Indianapolis, IN; David Johnson, University of Texas Southwestern Medical Center, Dallas, TX; Sarah Temin, American Society of Clinical Oncology, Alexandria; Sherman Baker Jr, Virginia Commonwealth University Health System Massey Cancer Center, Richmond; Joan H. Schiller, Inova Schar Cancer Institute, Fairfax, VA; Julie Brahmer and Thomas J. Smith, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Peter M. Ellis, Juravinski Cancer Centre, Hamilton; Natasha B. Leighl, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada; Giuseppe Giaccone, Georgetown University, Washington, DC; Paul J. Hesketh, Lahey Hospital and Medical Center, Burlington, MA; Ishmael Jaiyesimi, William Beaumont Hospital, Royal Oak; Bryan J. Schneider, University of Michigan Health System, Ann Arbor, MI; Gregory J. Riely, Memorial Sloan-Kettering Cancer Center, New York, NY; Joan Tashbar, Circle of Hope for Cancer Research, Orlando, FL; William A. Biermann, Einstein Medical Center Montgomery, East Norriton, PA; and Gregory Masters, Helen F. Graham Cancer Center and Research Institute, Newark, DE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.6065DOI Listing
October 2017

Radical Treatment of Stage II Non-small-cell Lung Cancer With Nonsurgical Approaches: A Multi-institution Report of Outcomes.

Clin Lung Cancer 2018 01 21;19(1):e11-e18. Epub 2017 Jun 21.

Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.06.007DOI Listing
January 2018

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.

Front Oncol 2017 31;7:113. Epub 2017 May 31.

Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449484PMC
May 2017

Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.

Ther Adv Med Oncol 2017 Jun 26;9(6):405-414. Epub 2017 Apr 26.

Division of Medical Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834017704329DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455881PMC
June 2017

Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes.

Authors:
James D McKay Rayjean J Hung Younghun Han Xuchen Zong Robert Carreras-Torres David C Christiani Neil E Caporaso Mattias Johansson Xiangjun Xiao Yafang Li Jinyoung Byun Alison Dunning Karen A Pooley David C Qian Xuemei Ji Geoffrey Liu Maria N Timofeeva Stig E Bojesen Xifeng Wu Loic Le Marchand Demetrios Albanes Heike Bickeböller Melinda C Aldrich William S Bush Adonina Tardon Gad Rennert M Dawn Teare John K Field Lambertus A Kiemeney Philip Lazarus Aage Haugen Stephen Lam Matthew B Schabath Angeline S Andrew Hongbing Shen Yun-Chul Hong Jian-Min Yuan Pier Alberto Bertazzi Angela C Pesatori Yuanqing Ye Nancy Diao Li Su Ruyang Zhang Yonathan Brhane Natasha Leighl Jakob S Johansen Anders Mellemgaard Walid Saliba Christopher A Haiman Lynne R Wilkens Ana Fernandez-Somoano Guillermo Fernandez-Tardon Henricus F M van der Heijden Jin Hee Kim Juncheng Dai Zhibin Hu Michael P A Davies Michael W Marcus Hans Brunnström Jonas Manjer Olle Melander David C Muller Kim Overvad Antonia Trichopoulou Rosario Tumino Jennifer A Doherty Matt P Barnett Chu Chen Gary E Goodman Angela Cox Fiona Taylor Penella Woll Irene Brüske H-Erich Wichmann Judith Manz Thomas R Muley Angela Risch Albert Rosenberger Kjell Grankvist Mikael Johansson Frances A Shepherd Ming-Sound Tsao Susanne M Arnold Eric B Haura Ciprian Bolca Ivana Holcatova Vladimir Janout Milica Kontic Jolanta Lissowska Anush Mukeria Simona Ognjanovic Tadeusz M Orlowski Ghislaine Scelo Beata Swiatkowska David Zaridze Per Bakke Vidar Skaug Shanbeh Zienolddiny Eric J Duell Lesley M Butler Woon-Puay Koh Yu-Tang Gao Richard S Houlston John McLaughlin Victoria L Stevens Philippe Joubert Maxime Lamontagne David C Nickle Ma'en Obeidat Wim Timens Bin Zhu Lei Song Linda Kachuri María Soler Artigas Martin D Tobin Louise V Wain Thorunn Rafnar Thorgeir E Thorgeirsson Gunnar W Reginsson Kari Stefansson Dana B Hancock Laura J Bierut Margaret R Spitz Nathan C Gaddis Sharon M Lutz Fangyi Gu Eric O Johnson Ahsan Kamal Claudio Pikielny Dakai Zhu Sara Lindströem Xia Jiang Rachel F Tyndale Georgia Chenevix-Trench Jonathan Beesley Yohan Bossé Stephen Chanock Paul Brennan Maria Teresa Landi Christopher I Amos

Nat Genet 2017 Jul 12;49(7):1126-1132. Epub 2017 Jun 12.

Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ng.3892DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510465PMC
July 2017

Uncommon EGFR mutations in advanced non-small cell lung cancer.

Lung Cancer 2017 07 27;109:137-144. Epub 2017 Apr 27.

Princess Margaret Cancer Centre, 610 University Avenue, Toronto, ON M5G 2M9, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.04.016DOI Listing
July 2017

Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?

J Clin Oncol 2017 Aug 2;35(24):2764-2771. Epub 2017 Jun 2.

Sierra Cheng, Erica J. McDonald, Matthew C. Cheung, Vanessa S. Arciero, Mahin Qureshi, Di Jiang, Natasha Leighl, and Kelvin K.W. Chan, University of Toronto; Mona Sabharwal, Alexandra Chambers, Dolly Han, and Kelley-Anne Sabarre, Canadian Agency for Drugs and Technologies in Health; Kelvin K.W. Chan, Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario; and Doreen Ezeife, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.6894DOI Listing
August 2017

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

J Clin Oncol 2017 Aug 5;35(22):2490-2498. Epub 2017 May 5.

Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5904DOI Listing
August 2017

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.

Front Oncol 2017 27;7:50. Epub 2017 Mar 27.

Division of Medical Oncology, Princess Margaret Cancer Centre , Toronto, ON , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2017.00050DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366319PMC
March 2017

Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.

Eur Respir J 2017 03 15;49(3). Epub 2017 Mar 15.

Dept of Radiation Oncology, Princess Margaret Cancer Centre and Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01428
Publisher Site
http://dx.doi.org/10.1183/13993003.01428-2016DOI Listing
March 2017